Legend Biotech is a multinational biopharmaceutical company focused on discovering and developing cutting-edge cell-based therapies with the ultimate goal of changing the way life-threatening diseases are treated.

Biotechnology

Legend Biotech

Dr. Guowei Fang has served as Senior Vice President, Global Head of Research and Early Development, since March, 2022. He is an accomplished scientist and pharmaceutical R&D leader who brings a wealth of experience in oncology and immunology to the role. Dr. Fang comes to Legend Biotech from Zymeworks Inc, where he served as SVP of Research and oversaw the development of novel platforms and a portfolio of multi-functional biologics and antibody drug conjugates. Prior to that, Dr. Fang led discovery and early development initiatives as Head of Discovery at Pharmacyclics, an AbbVie company. In that role, he built the Research, Discovery, Translation and Clinical Pharmacology organizations, delivered a broad pipeline of hematological assets and supported clinical development of IMBRUVICA®. Before joining Pharmacyclics, Dr. Fang worked at Genentech and AbbVie with a focus on oncology research and discovery. Prior to transitioning into pharmaceutical research and development, he was a faculty member at Stanford University leading cancer research initiatives.

Dr. Fang received his Doctor of Philosophy degree from University of Colorado under the mentorship of Dr. Thomas Cech and completed his postdoctoral training at Harvard Medical School under the mentorship of Dr. Marc Kirschner. He received his Bachelor of Science degree in biochemistry from Nanjing University. Dr. Fang has published over 60 manuscripts in cancer research and drug discovery and development, including primary publications in Science, Nature and Cell.

Guowei Fang

Dr. Zhu served as the vice president of strategy of Genscript Biotech Corporation (“GenScript”) from March 2010 to February 2017, served as the chief strategy officer of GenScript from February 2017 to July 2019, and has served as a consultant for GenScript since July 2019. Upon his appointment as executive director of GenScript on November 22, 2020, he resumed his role as the chief strategy officer of GenScript. Before joining GenScript, Dr. Zhu worked at California-based Clontech Laboratories, Inc. as a director of molecular biology from January 1990 to March 2000. Dr. Zhu founded Genetastix Corporation, Inc., a biotech company focused on yeast-based antibody discovery, and served as president and chief executive officer from May 2000 to December 2005. Dr. Zhu then worked at biotech companies in China, serving as vice president of research at Cathay Biotech, Inc. from July 2006 to December 2008, and as vice president of HUYA Biomedical Technology (Shanghai) Co., Limited from January 2009 to December 2009. Dr. Zhu obtained a Bachelor of Science of Biology degree from the East China Normal University in February 1982 and a Doctor of Philosophy in molecular biology and immunology from Stanford University in July 1989.

Zhu Li

Dr. Frank Zhang is Chairman of the Board of Legend Biotech and has been a non-executive director of GenScript Biotech Corporation (“GenScript”) since May 2022. Prior to 2022, he was chairman and an executive director of GenScript from 2015 to 2020. He co-founded the GenScript group in 2002 and has been the director of various group companies prior to GenScript becoming the holding company of the group companies pursuant to the corporate reorganization for GenScript’s initial public offering in 2015. In 2015, Dr. Zhang founded the Company as a subsidiary of GenScript, expanding GenScript’s business goal to research, manufacture and commercialize a broad range of immunotherapy treatments. Dr. Zhang served as Chairman of the Company’s Board of Directors from 2015 to November 2020 and served as the Company’s Chief Executive Officer from August 2020 to September 2020.

In 2018, Dr. Zhang was awarded Person of the Year at the China Healthcare Summit in recognition of his contribution to and significant impact on the healthcare field. Before founding GenScript, Dr. Zhang worked as a Principal Scientist at Schering-Plough from 1995 to 2002 where he received its Presidential Award. Dr. Zhang holds a Ph.D. in biochemistry from Duke University, a Master’s degree from Nanjing University and a Bachelor’s degree from Chengdu Institute of Geology.

Frank Zhang

Mr. Marc Harrison has served as Vice President and General Counsel since January 2022. He brings over 20 years of experience in healthcare and life sciences to Legend Biotech. Most recently, Mr. Harrison was Vice President, General Counsel and Head of Compliance for Breckenridge Pharmaceutical, Inc., where he led a team responsible for all legal and compliance matters.

He previously held senior legal and leadership positions at Ipsen Biopharmaceuticals, Medco Health Solutions and WebMD. Mr. Harrison began his legal career with the international law firms Shearman & Sterling LLP and Alston & Bird LLP, where he focused on securities transactions, leveraged financing, and mergers and acquisitions.

Mr. Harrison earned his Juris Doctor degree, cum laude, from New York University School of Law and his Bachelor of Arts degree in political science from Emory University, where he was elected to Phi Beta Kappa.

Marc Harrison

Mr. Tomas Heyman previously served as the President of Johnson & Johnson’s Corporate Venture Capital Group, the venture capital arm of Johnson & Johnson, a Global Healthcare Company from 2015 to September 2019 and as the Global Head of Business Development for Johnson & Johnson’s Pharmaceutical Group from 1992 to 2015. In addition, Mr. Heyman previously served as Chief Executive Officer of Janssen Pharmaceutica N.V., a pharmaceutical company, from 2008 to 2016. Mr. Heyman has served as a director of OptiNose, Inc., a specialty pharmaceutical company, since December 2020, a director of Akero Therapeutics, Inc., a biotechnology company, since June 2020 and a director of Adagio Therapeutics Inc., a biopharmaceutical company, since June 2021. Mr. Heyman graduated as Master of Law from the K.U. Leuven in Belgium. He continued with post-graduate studies in International Law in Geneva, Switzerland, and post-graduate studies in business management at the University of Antwerp in Belgium.

Tomas J. Heyman

Dr. Li Mao currently serves as Chief Medical Officer for SciClone Pharmaceuticals, Inc., a position he has held since June 2022. Prior to that, Dr. Mao served as Chief Medical Officer of Sino Biopharmaceutical Co., Ltd. from May 2021 to June 2022, Chief Executive Officer of Livzon Bio from March 2021 to April 2021 and Chief Executive Officer of Xcovery Holdings, Inc. from November 2018 to March 2021. Dr. Mao also served as Senior Vice President and Chief Medical Officer of Betta Pharmaceuticals Co., Ltd. from March 2018 to March 2021 and Vice President at Johnson & Johnson from June 2016 to February 2018. In addition, he served as a Professor at the MD Anderson Cancer Center from 2004 to March 2009 and a Professor at the University of Maryland, Baltimore from March 2009 to June 2016. Dr. Mao also served as a member of the board of directors of Betta Pharmaceuticals Co., Ltd, which is publicly listed on the Shenzhen Stock Exchange, from April 2018 to March 2021. Dr. Mao holds a Medical Doctor’s degree from Nanjing Medical University. Dr. Mao also completed a postdoctoral fellowship in cancer genetics at The John Hopkins University School of Medicine.

Li Mao

Mr Chong Yang has served as Vice President of Commercial Development, Greater China since July, 2018. Formerly, Mr Yang held various sales and marketing leadership roles with increasing responsibilities in multinational pharmaceutical companies including Roche Oncology, Bayer Oncology, and Novartis Oncology. He brings more than 17 years of commercial experience and has extensive expertise in promoting and launching products including GLIVEC, NEXAVAR, AVASTIN, and RITUXAN in the China market.

Mr Yang earned his Master of Medicine degree from Nanjing University, China, and served as a Surgical Resident at Zhongda Hospital at Southeast University, China.

Chong Yang

Dr Tracy Luo has served as Vice President of Clinical Development, Greater China, since May, 2018. Dr Luo has a comprehensive understanding of the Chinese regulatory environment and dynamics and has more than 15 years of experience advancing clinical development programs in the oncology and hematology therapeutic areas. Previously, Dr Luo led multiple global oncology and hematology products through the clinical development stage at AstraZeneca, Amgen, and Sanofi. Her efforts led to numerous successful regulatory filings and commercial launches, including IRESSA, FASLODEX, BLINCYTO, KYPROLIS, and ELOXATIN. Previously, Dr Luo spent more than 6 years as a pharmacology research scientist at Fudan University Shanghai Medical School, China.

Dr Luo earned her Doctor of Medicine degree from Qingdao Medical College, China, and a Master of Science degree in pharmacology at Fudan University, China.

Tracy Luo

Mr Steve Gavel has served as Vice President of Commercial Development since July, 2018. He brings over 28 years of commercial experience in biotech start-ups, leading pharmaceutical and medical device organizations.

Most recently, Mr Gavel worked at Celgene Corporation, where he led US CAR-T commercial development activities for their bb2121 program. In this role, he led commercial launch strategy and execution planning in the United States. Prior to Celgene, Mr Gavel led VELCADE marketing strategy and execution at Takeda Oncology, where he served as Senior Marketing Director.

Prior to Takeda Oncology, Mr Gavel held multiple sales, marketing and market access leadership positions in companies such as Syntex, Immunex, Johnson & Johnson, and IMS Health.

Mr Gavel earned his Bachelor of Science degree in finance and business administration from Millersville University in Millersville, Pennsylvania, USA.

Steve Gavel

Patrick Casey is the Senior Vice Dean of Research at the Duke-NUS Medical School and a James B. Duke Professor of Pharmacology and Cancer Biology at Duke University. Dr. Casey joined Duke University Medical Center as an Assistant Professor of Molecular Cancer Biology and Biochemistry in 1990. In 2005, Dr. Casey relocated to Singapore to spearhead the development of the Signature Research Programmes at Duke-NUS, where he currently oversees the administration and strategic planning of these programmes, and mentoring of faculty and trainees. He was also the founding Director of the Duke Center for Chemical Biology—an organization of Duke scientists dedicated to research and training in the application of fundamental chemical principles to the study of biology and the basis of disease and therapies. A recognized authority in the fields of lipid modifications of proteins and in G protein signaling, Dr. Casey has received several awards for his work, including the Established Investigator Award from the American Heart Association in 1992 and the Amgen Award from the American Society of Biochemistry and Molecular Biology in 2000. He was elected a Fellow of the American Association for the Advancement of Science in 2012. Dr. Casey serves on advisory panels for Agency for Science, Technology and Research (A*STAR), National Research Foundation (NRF) and National Medical Research Council (NMRC). Dr Casey received his PhD in Biochemistry from the Brandeis University in 1986 and did postdoctoral work at the University of Texas Southwestern Medical Center in Dallas.

Patrick Casey

Ms Wang is the President of GenScript Inc. and a board member for Legend Biotech Corporation, responsible for the companies’ strategies and overall operational management. Prior to joining the organization, she worked as an Environmental Monitoring Engineer at Shenzhen Futian Environment Protection Surveillance Station for nearly a decade.

Ms Wang holds several advanced degrees, including a Master of Science degree from Wuhan University, China, in August 1993; a Master’s degree in Computer Sciences from Bridgeport University in Bridgeport, Connecticut, USA; and an Executive Master of Business Administration degree from the China Europe International Business School, China.

Sally Wang

Shu (Simon) Wu joined Legend Biotech in October 2017 as the head of the Research II Institute and ascended to the position of Vice President of Research in March 2021 before earning the title of General Manager of Greater China in August 2022. As General Manager of Greater China, Mr. Wu is responsible for operations management.

Prior to joining Legend Biotech, Mr. Wu was the Vice President of Operations for the Discovery Biology Business Unit at GenScript Inc., leading antibody therapeutics discovery and operations activities. Mr. Wu is the co-inventor of 30 patents in the field of immunotherapy and has more than 12 years of therapeutic antibody discovery and development, organizational capability building, and management experience. He has contributed to the development of successful novel discovery platforms and has led many antibody and chimeric antigen receptor T-cell (CAR-T) candidates into clinical development.

Mr. Wu received his Master of Science in Environmental Biology from the Chinese Academy of Science, China, and his Bachelor of Arts in Microbiology from Nanjing Agriculture University, China.

Shu Wu

Lori Macomber has served as Vice President of Finance since March, 2021. Prior to joining Legend Biotech, she held various financial positions within the life science industry, including experience in external and internal auditing, financial planning and analysis and controllership at Pharmacia, Eli Lilly, and AMETEK as well as privately held consulting company Kromite. Ms. Macomber holds a Bachelor of Science in Accounting from Pennsylvania State University and is a Certified Public Accountant.

Lori Macomber

Dr. Ying Huang currently serves as Chief Executive Officer of Legend Biotech. He sits on the Board of Directors of Legend, as well as Quanta Therapeutics.

Dr. Huang brings over 9 years of experience in research and development at major multi-national pharmaceutical companies and 12 years of experience as a biotechnology analyst on Wall Street.

Dr. Huang was a Managing Director and Head of Biotech Equity Research at Bank of America Merrill Lynch where he led a team of analysts covering more than 30 biotechnology companies that encompass a wide range of therapeutic areas. His knowledge and expertise have been recognized by the Institutional Investor survey as a top ranked biotechnology analyst on Wall Street. Dr. Huang previously worked at Wachovia, Credit Suisse, Gleacher and Barclays before joining Bank of America Merrill Lynch. Besides providing investment research to investors, Dr. Huang and his team conducted due diligence for numerous successful initial public offerings (IPOs) and follow-on offerings in the biotechnology sector.

Prior to his Wall Street career, Dr. Huang was a Principal Scientist at Schering-Plough in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. He is the co-author of multiple patents and peer reviewed publications. Dr. Huang received his Doctor of Philosophy in Bio-organic Chemistry from Columbia University. He also studied in the Special Class for the Gifted Young at the University of Science and Technology of China and Columbia Business School.

Ying Huang

Dr. Lida Pacaud joined Legend Biotech as the Vice President of Clinical Development in January, 2021. Most recently, Lida served as the Global Clinical Program Head and Executive Medical Director in Cell & Gene unit at Novartis. Prior to that, Lida worked at Roche and Wyeth. She has been the Medical Lead on several Phase I, II & III trials, including 3 major regulatory submissions to the FDA, EMA and other worldwide health authorities for KYMRIAH®, AFINITOR® and AVASTIN®. Lida has covered programs in breast cancer, brain tumors, sarcomas, Gastrointestinal and lung neuroendocrine tumors, diffuse large B-cell lymphoma, follicular lymphoma, and acute lymphoblastic leukemia. In her role in Cell & Gene unit in Novartis, Lida led clinical development and filling of KYMRIAH, first approved CART therapy worldwide that was also awarded the esteemed Prix Galien USA Award for Best Biotechnology Product in 2018. On this program, Lida led US breakthrough therapy designation and EU PRIME designation for DLBCL, as well as Regenerative Medicine Advanced Therapy (RMAT) designation for follicular lymphoma, and she oversaw large global cross-functional clinical teams up to 100 individuals. Lida has also experience in BD&L activities as clinical evaluator of external cell therapy opportunities.

Dr. Lida Pacaud holds a Doctor of Medicine degree and certification in Pediatrics from Tbilisi State Medical University and has trained in Pediatric Oncology and hematology in France.

Lida Pacaud

Mr Alan Kick has served as Vice President of Global Quality since August, 2018. Prior to joining Legend Biotech, Mr Kick was Executive Director of Quality Operations at Celgene Corporation, responsible for the Global External Quality, Cell Therapy Quality, and Global Quality Supply Chain organizations. He previously held positions of increasing responsibility at Dendreon, Wyeth, Johnson & Johnson, and Hoffmann-La Roche. Mr Kick has nearly 30 years of experience in the pharmaceutical industry, including solid oral dosage, semi-solids, biologics, vaccines, sterile lyophilized products, cellular therapies, active pharmaceutical ingredient (API), commercialization, development, and laboratory management.

Mr Kick received a Bachelor of Science degree in biology from The College of New Jersey in Ewing, New Jersey, USA, and a Master of Science degree in business management from New Jersey Institute of Technology in Newark, New Jersey, USA.

Alan Kick

Ms Liz Gosen has served as Senior Vice President, Global Technical Operations since May, 2019. Prior to joining Legend Biotech, she was Vice President of Biologics Operations at Eli Lilly where she was responsible for the manufacturing, warehouse, and supply chain organizations for a 2-suite multi-product commercial and clinical monoclonal antibody (mAb) manufacturing facility.

During her 25-year career she has developed a broad experience in biotechnology manufacturing operations through assignments in the following areas: multiple large-scale manufacturing facility capital design/builds and start-ups, process engineering support and management, facility and utilities management, site process technology transfers, and successful process validation as well as operations, logistics, and validation management.

Ms Gosen has international commercial scale manufacturing experience as a Business Unit Leader of an Eli Lilly large-scale mAb facility in Ireland. She was responsible for the organizational build and development of the operations organization from the commissioning and qualification support phase through to FDA approval and commercial operations. Ms Gosen has extensive global regulatory inspection experience and has been directly involved in the worldwide regulatory submission, pre-approval inspection, and launch of five biologics products.

Ms Gosen holds a Bachelor of Science Degree in Materials Science & Engineering with a minor in Biology from Lehigh University, Pennsylvania, USA, and an MBA of Finance from Seton Hall University, New Jersey, USA.

Liz Gosen

Dr Yuhong Qiu has served as Vice President of Global Regulatory Affairs since May, 2018. Previously, Dr Qiu served as Executive Director of Regulatory Affairs at Novartis Oncology, where she worked for 12 years with increasing responsibilities. She has broad regulatory expertise spanning across both small and large molecule (biologics) development. Dr Qiu has led numerous successful global regulatory filings from first-to-human studies to marketing authorization applications. Before joining Novartis Oncology, Dr Qiu worked for 8 years at Johnson & Johnson, where she led a team of scientists in drug discovery and gained rich experience in drug candidate selection and characterization and preparation of nonclinical documents for first-in-human studies.

Dr Qiu received her Doctor of Philosophy degree and completed her postdoctoral training from the Baylor College of Medicine in Houston, Texas, USA. She received her Bachelor of Science degree in biochemistry from Wuhan University, China. Dr Qiu has authored or co-authored more than 30 publications in peer-reviewed journals.

Yuhong Qiu

Dr. Ji has served on the board of directors at Legend Biotech since May 2020. Dr. Ji is Chairman and CEO of Elpiscience Biopharmaceuticals, a clinical stage immunotherapy company that he co-founded. He is also a Venture Partner of Lilly Asia Ventures (LAV). Prior to that Dr. Ji was Global Head and Vice President of Roche for Business Development in Asia and Emerging Markets. In this role, Dr. Ji was responsible for driving the strategy and execution of business development activities in a large territory encompassing over 100 countries. During his tenure, Dr. Ji championed and oversaw the closing of a number of key transactions between Roche and partners worldwide. He managed a global team and established a strong business network in key countries including: China, Japan, Korea, Australia/New Zealand, Russia and Brazil.

A repeat entrepreneur himself, Dr. Ji started his career at the Procter & Gamble Pharmaceuticals with increasing responsibilities in drug R&D and business development. He co-founded and managed as CEO of PharmaLegacy Laboratories in Shanghai in 2008, which became a premium CRO providing high-quality drug discovery services to a large global clientele until today. Dr. Ji has been a highly respected leader and a sought-after speaker in global business forums. He was also an avid community builder exemplified by completing one of the longest services as a board member of the BayHelix Group, a community of business leaders of Chinese heritage in the life sciences.

Dr. Ji received his Doctor of Medicine from China Medical University, China; a Doctor of Philosophy degree from University of Sheffield, UK; and a Master of Business Administration degree from the University of Chicago, USA.

Darren Ji

Mr. Yau has served on the board of directors at Legend Biotech since May 2020. He has over 23 years of experience in accounting, finance, mergers and acquisitions, investments, corporate finance audit, and risk management. Most recently, Mr. Yau served as the non-Executive Vice Chairman and Group Chief Financial Officer at AMTD Group where he led the strategy development, corporate finance and investment function. From September 2011 to March 2016, he worked at Ernst & Young China Practice as a partner and risk advisory China South market leader, serving clients in Greater China, where he advised on finance, management, and business issues. From January 2006 to July 2011, he worked at Protiviti Shanghai Co., Ltd. serving clients in Greater China, and as a managing director and Shenzhen office leader, where he was primarily responsible for overall management of the company. From 1997 to 2006, he worked at PricewaterhouseCoopers and Arthur Andersen & Co. in various roles with his most recent position as a senior manager in the risk consulting practice.

Mr. Yau is a certified public accountant in the United States, a fellow member of the Hong Kong Institute of Certified Public Accountants in China, and a certified internal auditor with the Institute of Internal Auditors.

Mr. Yau graduated from the Lundquist College of Business of University of Oregon in the United States with a Bachelor of Arts degree in Accounting in 1997. Mr. Yau obtained his Executive Master of Business Administration degree from a joint school program by the Kellogg School of Management, Northwestern University and the Hong Kong University of Science and Technology China in 2019.

Philip Yau

Dr. Dong Geng joined Legend Biotech in 2018. Since then, Dr. Geng has taken increasing responsibilities primarily in Legend’s R&D portfolio development. She is responsible for non-clinical safety, pre-clinical and clinical pharmacology and translational sciences. Dr. Geng brought more than 22 years of biopharma industry experience to Legend. Prior to joining Legend, Dr. Geng had worked in leading biotech and pharmaceutical companies including Johnson and Johnson, BMS, Regeneron, Eli Lilly, and Merck. She has extensive experience in translational development of biologics especially immune-oncology therapies. During her career she has contributed and led numerous IND submissions and at least 7 successful BLA filings.

Dong received her Ph.D. in Biochemistry from Boston College.

Dong Geng

Dr. Sanders has served on the board of directors at Legend Biotech since May 2020. Dr. Sanders has also been a member of the board of directors at Molecular Templates, Inc. since December 2019 and at AbGenomics since March 2020.

Dr. Sanders previously served as the Strategic Advisor to the Office of the Celgene Chief Medical Officer from March 2018 to November 2019. Her responsibilities included ensuring effective integration of Juno’s Development Organization into the Celgene Organization, specifically the unique chimeric antigen receptor T-cell (CAR-T) aspects, advising the label-enabling CAR-T legacy Juno program (JCAR017), and advising the Chief Medical Officer and his leadership team on evolving the clinical development organization.

Prior to her role as Strategic Advisor, Dr. Sanders was a Member of the Juno Therapeutics Executive Committee as Executive Vice President of Development Operations, with responsibilities for strategic operations, quantitative sciences, biosample and clinical operations from January 2017 to March 2018.

Dr. Sanders was a Member of the Genentech/Roche Late Stage Portfolio Committee from 2009 to 2017, and Global Head of the Genentech/Roche Late Stage Clinical Operations from 2012 to 2017, with responsibility for leading employees in planning and conducting global development and local clinical trials in over 70 countries.

Dr. Sanders has directly contributed and/or provided oversight in developing multiple pharmaceutical products, including a CAR-T cell therapy for Non-Hodgkin lymphoma.

Dr. Sanders holds a Bachelor of Science and a Master of Science in statistics, graduating Magna Cum Laude from the University of the Philippines, Philippines. She also received a Master of Arts and a Doctor in Philosophy in statistics from the Wharton Doctoral Program at the University of Pennsylvania, USA.

Leadership Team

About

Team members

Other teams at Legend Biotech

Board of Directors

CEO and Executive Team

Discover similar companies